Legacy Wealth Asset Management LLC Grows Stock Holdings in argenx SE (NASDAQ:ARGX)

Legacy Wealth Asset Management LLC lifted its stake in shares of argenx SE (NASDAQ:ARGX) by 5.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,368 shares of the company’s stock after purchasing an additional 68 shares during the period. Legacy Wealth Asset Management LLC’s holdings in argenx were worth $539,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Stifel Financial Corp increased its stake in shares of argenx by 9.6% in the 3rd quarter. Stifel Financial Corp now owns 7,730 shares of the company’s stock worth $3,800,000 after acquiring an additional 680 shares during the last quarter. Northern Trust Corp grew its stake in shares of argenx by 41.1% in the 3rd quarter. Northern Trust Corp now owns 39,936 shares of the company’s stock valued at $19,634,000 after buying an additional 11,627 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of argenx during the 3rd quarter worth approximately $223,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of argenx during the 3rd quarter valued at approximately $564,000. Finally, Toronto Dominion Bank grew its position in argenx by 174.2% in the third quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock worth $131,000 after acquiring an additional 169 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $448.00 target price on shares of argenx in a research report on Monday, June 24th. JPMorgan Chase & Co. lowered their price objective on shares of argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. Bank of America reissued a “buy” rating and set a $607.00 target price (up previously from $535.00) on shares of argenx in a research note on Monday, June 24th. Piper Sandler increased their price target on shares of argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. Finally, Scotiabank lifted their price objective on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a report on Tuesday, March 26th. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average target price of $525.42.

argenx Trading Down 0.0 %

Shares of NASDAQ ARGX opened at $435.29 on Friday. The company has a 50-day simple moving average of $388.03 and a 200-day simple moving average of $386.43. argenx SE has a 12 month low of $327.73 and a 12 month high of $550.76.

argenx (NASDAQ:ARGX) last released its earnings results on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The firm had revenue of $412.51 million during the quarter, compared to analysts’ expectations of $404.03 million. During the same period in the previous year, the firm posted ($0.52) earnings per share. As a group, analysts expect that argenx SE will post -2.92 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.